During the preclinical science plenary session from 2017's Immuno-Oncology 360° conference, Dr Charles Drake's talks about "Sequencing of Combination Agents."

Dr Drake is Director, Genitourinary Oncology and Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Previously, he was an associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine. He also serves as Co-Director of the Prostate Cancer Multidisciplinary Clinic. His areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder and testes.

Dr Drake graduated with a BS in electrical engineering and MS in biomedical engineering from Rutgers University in Piscataway, NJ. He then received a PhD in immunology from the National Jewish Center for Immunology, and in 1997 completed an MD at the University of Colorado Health Sciences Center. He conducted an internal medicine residency on the Osler Service at Johns Hopkins, and in 2002 he completed a fellowship in medical oncology, also at Johns Hopkins. He joined the Johns Hopkins faculty as an assistant professor in 2002.

Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

Sequencing of Combination Agents in Immuno-Oncology with Dr Charles Drake

Share

Embed